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ABSTRACT 
 
 
  Murine polyomavirus, a double stranded DNA virus that causes multiple kinds of tumors, 
was one of the first viruses ever sequenced, and has proven to be an invaluable model in 
virology, cancer research, molecular biology and immunology.  The purpose of this MQP was to 
use FACS staining to isolate viral antigen (VP1 major capsid protein)-specific B-lymphocytes 
using a double stain for VP1 and B220.  A major portion of the project focused on designing a 
treatment to overcome the non-specific binding of antibodies to cell surface sialic acid residues. 
The enrichment of antigen-specific B cells succeeded, and these cells can be analyzed for gene 
expression patterns to further understand these virus-specific cells of the humoral immunity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
TABLE OF CONTENTS 
 
 
Signature Page ……………………………………………………………………….  1 
 
Abstract ………………………………………………………………………………  2 
 
Table of Contents ……………………………………………………………….……  3 
 
Acknowledgements …………………………………………………………………..  4 
 
Background …………………………………………………………………………..  5-15 
 
Project Purpose ……………………………………………………………………….  16 
 
Methods ………………………………………………………………………………  17-25 
 
Results ………………………………………………………………………………..  26-42 
 
Discussion ……………………………………………………………………………  43-46 
 
Bibliography …………………………………………………………………………  47-48 
 
 
 
 
 
 
 
 
 4 
ACKNOWLEDGEMENTS 
 
 
 First of all, many heartfelt thanks must go out to the Welsh lab at University of 
Massachusetts Medical School in Worcester, Massachusetts.  I particularly wish to thank Eva my 
advisor there, and Heath, Thuvan, Tatiana for helping me learn different assays which made the 
project possible.  Also I would like to thank Dr. Donald Tipper, at UMMS, for providing the 
genetically engineered GFP-VP1 that yielded such consistent and invaluable data. Gratitude also 
goes out for the VP1-specific hybridoma that was provided by Aaron Lukacher's lab at Emory 
University, and for the recombinant VP1 protein used in ELISA and ELISPOT assays provided 
by Robert Garcea (UCHSC, Denver).  Finally many accolades go to Dave Adams my WPI 
advisor whom helped setup the project. 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
BACKGROUND 
 
 
Introduction 
 
Mouse Polyomavirus (PyV) belongs to the Papovavirus family.  It was first isolated by S. 
Stewart and is still a widely studied virus for many reasons.  First, this virus produces a large 
number of tumor types in its natural host, neonatally infected mice. An understanding of this  
tumor induction in mice will be helpful for cancer research in humans. Secondly, PyV-infected 
mice provide a good model to study immune responses to virus infection. PyV does not cause 
disease in adult mice with a normal immune system, but replicates to higher titer and causes 
pathology in immuno-compromised mice. This outcome of infection is similar to infections of 
humans with BK and JC viruses which are human polyomaviruses.
 
 
Viral Characteristics 
 The mouse polyoma virus possesses a double stranded, circular and supercoiled DNA of 
genome size of approximately 5.3 kb.
 
 The genome is non-enveloped and has an icosahedral 
capsid with a diameter of 40 – 55 nm. The nucleocapisds are isometric and they have 72 
pentamers of capsomer proteins per nucleocapsid (Büchen-Osmond, 2004). Most of the virus is 
composed of structural proteins. Nucleic acid (DNA) makes up 12% of a complete virion.  
 
Host Factors 
 Several polyomaviruses exist, but each is specific for only a certain species.  The murine 
polyomavirus is only capable of replication in mice, not in any similar rodents (rats, chinchillas, 
hamsters, etc).  But there are different polyomaviruses able to infect other animals. However the 
speed of murine PyV’s life cycle and high rate of infectivity (in vitro and in vivo), in mice versus 
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other PyV is why they are used as model organisms in experimental research (Harbel, 1963).  
These other PyV can transform rat, hamster and human cells in vitro.  Conversely, DNA can be 
injected or transfected making replication of viral DNA unnecessary. 
The most frequent tumors induced by polyomavirus are mixed tumors of the salivary 
glands, respiratory tract mucous glands, subcutaneous sarcomas, mammary tumors and thymic 
epitheliomas (Row, 1960).  Most of the in vivo experimental work is done by inoculating the 
newborn pups with the virus, so they can express the tumor induced by the virus. Then any 
changes in their health is closely followed and examined. The ability of the polyoma virus to 
induce tumors depends on the age of the host at the time of inoculation. Adult animals develop 
PyV-induced pathology (tumors) only if they are immunocompromised.  
 
Genome Characteristics  
 Since polyomavirus was one of the first viruses to be sequenced and studied, its gene 
arrangement and regulation is well understood.  Inside the virions, the DNA is supercoiled and 
compact. Murine polyomavirus’ genome is composed of a 5.3 kb closed circular doubled 
stranded DNA.  Despite its small size, the genome is known to encode 6 genes (Brinkman et al., 
2004).  This large amount of information packaging is accomplished by overlapping genes, and 
reading from both strands. The majority of viruses read only from one strand (+ strand) 
(University of Leicester, 2005). 
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Figure 1. Polyomavirus Genome (University of Leicester, 2005). 
 
 The polyomavirus origin of replication (Fig.1 left middle) lies between non-coding areas 
responsible for transcriptional control. Three different T-antigens (large, middle, and small) are 
also encoded (on the opposite strand coding the structural proteins) (see table 1).  PyV-infected 
mice with tumors express these T-antigen proteins in  the tumor tissue. VP1 (major capsid 
protein) is encoded by a devoted open reading frame (no stop codons). This differs from VP3, 
which is contained within VP2 as an overlapping gene. VP1/2/3 encode viral structural proteins. 
Yet, if VP2 and VP3 are defective, viral capsids can still form from VP1 alone. 
T-antigen: Large T Small T Middle T 
Size (amino acids): 785 195 421 
Table 1. T-Antigen Lengths (University of Leicester, 2005). 
 
 VP1 is the only protein on the outside of the virion, and is responsible for attachment “to 
host cell membrane molecules containing terminal sialic acids” (Caruso et al., 2003).  Almost 
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every murine cell contains surface sialic acids, which allows the virus to be efficient at binding.  
Four pockets on the VP1 pentamer are able to accommodate the sialic acids (see figure 2).  
 
 
 
Figure 2.  Interaction of VP1 with Sialic Acid Residues.  Inset in the upper right quadrant shows VP1 bound to a 
sialic acid (α-2,6-linked sialic ) residue.  VP1 residues that interact via hydrophobic reactions with sialic acid 
receptor are shown as arrows, while hydrogen bonds with receptor are depicted as broken lines (Bauer  et al., 1999). 
 
Pocket 1 and 2 allow binding to the majority of sialic acids. Pocket 3 is able to bind alpha 2,6-
linked sialic acids that would be part of a branched chain receptor. It is not known what pocket 4 
is able to bind, but it may accommodate more complex oligosaccarides or proteins "in short O-
linked glycans" (Stehle et al., 1994). A VP1 mutant will not be able attach correctly (see figure 
3).  
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               Figure 3. VP1 Monomer Bound to 3’Siayl lactose (receptor analogue) (Stehle et al., 1994). 
 
Several loops in the VP1 monomer bind the sialic acid. “Residues 78 to 89 of the BC2 
loop of the clockwise neighbor and residues 137 to 159 DE loop” of VP1 are crucial in allowing 
binding to sialic acids" (Stehle et al., 1994).  A mutation in either VP1 Asn 93, Arg77 or His298 
will destroy attachment ability and infectivity (see figure 4).  
VP2 and VP3 are myristylated, and are thought to initiate endocytosis. The particles are 
guided to the nucleus by cytoskeleton-endocytic valcuole interactions (Leicester, 2005). Viral 
particles then enter the cell nucleus through nuclear pores, after which uncoating takes place (due 
to change in environment, it occurs spontaneously).  If the virus contains VP2/VP3 mutations, 
the virus cannot uncoat and undergo replication (since VP2 and VP3 are involved in the 
uncoating). 
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             Figure 4. Binding of VP1 to 3-Sialyl Lactose (Stehle et al., 1994). 
 
Once inside the nucleus, viral DNA associates with histones H2A, H2B, H3 and H4 of 
the host cell. This complex is called a “viral mini-chromosome” (Baek, 2005).  The viral genes 
are expressed in a temporally coordinated fashion. Early genes are expressed first (before DNA 
replication) and proceed until late infection. The early proteins are non-structural (regulatory), 
and they initiate replication.  As soon as viral DNA replication begins, a switch occurs to the late 
genes. These late genes are responsible for structural proteins (VP1, VP2, and VP3).  Lastly, 
there is a regulatory region, composed of enhancers, origin of replication and transcription 
promoters. The entire polyoma life cycle is shown in Figure 5. 
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                                       Figure 5.  Polyomavirus Life Cycle (University of Leicester, 2005). 
 
 Transcription of the viral mini-chromosome to produce early mRNAs is 
completed by RNA polymerase present in the host cell. Around the origin of replication 
there are cis-acting regulatory signals, which guide transcription and T-antigens (trans-
regulatory proteins). The T-antigens in turn direct further transcription and translation. 
Utilizing alternative splicing, 3 different early mRNA/T-antigens are produced (large, 
middle and small).  The large-T antigen autoregulates transcription in the early portion of 
the promoter by binding it (see figure 6) (University of Leicester, 2005). 
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                        Figure 6. Polyomavirus Late and Early Regions (University of Leicester, 2005). 
 
 Also contained within the promoter are enhancer components, allowing activity (T-
antigen transcription) in recently infected cells. Even though small T-antigen is not needed for 
viral replication, it enhances transcription of the late promoter (by binding to cellular proteins). 
When the large T-antigen concentration rises, it binds the origin of replication in the viral 
genome. DNA replication begins, and the late promoter becomes active. This causes early gene 
transcription to halt and switch to the infection’s late phase. The T antigens enhance replication 
of viral DNA replication (binds the enhancer), and also transactivate late gene promoters. “After 
the onset of DNA replication, the balance between early and late gene expression is quickly 
reversed in favor of late products; by late in infection, late messages exceed the early ones by a 
factor of 20-80” (Liu and Carmichael, 1993).  
The mechanism of early-late switch is not completely understood, but it is believed the 
large TAg (T-antigen) binds to a region opposite the viral origin of replication, and initiates viral 
replication. Experimental data has suggested that the “large TAg also transactivates the late 
promoter and represses transcriptional activity of early genes” (Liu and Carmichael, 1993). After 
replication, copies of DNA with the late promoter are then available for binding the 
transactivator. Cells that do not have viral DNA replication will not undergo a switch to late gene 
products. If a mutant virus has a deletion in the ori, TAg binding sequences, or frame-shift 
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mutations in the early region, the late gene product transition does not occur. Middle T-antigen 
may also be involved by altering host signal transduction pathways, which then modifies 
transcription factors (Liu and Carmichael, 1993).  
 DNA replication occurs due to a rise in the expression of Large T-antigen. It will bind to 
“DNA polymerase alpha & s/s DNA binding protein, both involved in DNA replication  p53 & 
p105" (University of Leicester, 2005). Mouse polyomavirus relies completely on host cell 
machinery for its replication and assembly (since it has a limited genome size, it can not encode 
much). Viral genome replication occurs as T-antigen and DNA polymerase alpha interact 
directly. Tumor suppressor proteins bind to T-antigen, causing them to be inactivated. Cells 
previously stuck in G1 then are able to enter S phase (synthesis), again furthering DNA 
replication. T-antigen produces an environment conducive to viral replication, but also allows 
cells to replicate when they normally would not.  By doing this, the virus transforms some cells 
into tumorgenic ones.  
 The frequency at which transformation occurs is a relatively low 1 per 10
5
 cells in 
various cultured somatic mouse cells. The middle T-antigen also associates with “phosphatase 
2A (PP2A), Src family tyrosine kinases, phosphatidylinositol 3-kinase (PI-3K) and an adaptor 
protein, Shc.  They are necessary for cellular transformation” (University of Leicester, 2005).  
Interestingly, a single point mutation in position 250 (tyrosine to serine) prevents binding to Shc. 
Such mutant infected mice have different tumor morphology (University of Leicester, 2005). 
   
Viral Assembly and Release 
 Polyomavirus proteins are first synthesized in the cytoplasm (on ribsomes), but need to 
get to the nucleus for virion assembly. These VP1, VP2 and VP3 structural proteins contain 
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nuclear localization signals which direct their aggregation in the nucleus. Chaperon proteins 
(hsc70 family) recognize these signals, bind the capsid proteins and escort them to the nucleus 
(Garcea et al., 2003). The capsid proteins self assemble in the nucleus (this has also been 
demonstrated in vitro) (Schmidt et al., 2000).  If insect cells are infected with baculovirus 
expressing VP1, VP1 capsosomers are able to self assemble (Garcea et al., 1995). During 
polyomavirus infection host cell histones aid in packing the viral mini-chromosome in the newly 
formed capsids (by binding the capsids, and the assembly occurs spontaneously). A few of the 
newly formed virus particles are transported to the cell surface via cytoplasmic vacuoles (see 
figure 7 for structure). Most of the viral particles are released when the cell lyses. The virus 
interferes with normal cell growth by inhibiting apoptotic signals, which would normally lead to 
cell death (typical of most cancerous cells).  Such interference is suspected to effect cellular 
metabolism and membrane synthesis, causing cell membrane weakening (the exact mechanism 
has not been determined). A weakened membran allows virons to escape easily during the 
release phase. The entire MPyV infection and replication (resulting in lysis) only takes 24-48 
hours in vivo. Such an infection is also dependant on multiplicity of infection and which cell type 
is infected (University of Leicester, 2005). 
 
 
 
 
 
 
Figure 7. Complete Mouse Polyomavirus Virion (University of California, 2004).  
The Outer shell contains 360 copies of VP1 (in pentamers). 
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 Overall, despite being one of the simplest and smallest viruses, polyoma continues to 
prove its usefulness as a viral model. As recombinant DNA technology continues to advance, 
more and more details are elucidated from murine polyomavirus. Just like human polyomavirus 
(BK and JC), it produces an infection that is persistent and often silent in immuno-competent 
hosts. Thus, information gleaned from murine polyomavirus is relevant to human immunology as 
well. 
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PROJECT PURPOSE 
 
  As discussed in the Background, Murine polyomavirus (MPyV) uses alpha 2-3 sialic acid 
residues present on the surface of many types of mammalian cells as receptors. But, the virus 
also engages antigen-specific B cell receptors on the surface of B-cells, eliciting an immune 
response.  The purpose of this project was to isolate B-cells containing B-cell receptors (surface 
antibody), specific for the virus.  If such cells can be isolated, they can be used to analyze 
changes in gene expression profiles that occur when B lymphocytes respond to viral antigens. 
Fluorescence activated cell sorting (FACS) was chosen as the isolation technique, using a double 
immunostain for VP1 (the main polyomavirus capsid protein) and B220 (CD45R) (a surface 
marker specific for B-cells).  A substantial portion of the project focused on alleviating high 
levels of non-specific binding of VP1 to sialic acid residues present on the surface of B-cells. 
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MATERIALS AND METHODS 
General Lab Reagents 
Source / Catalog Id (if applicable) Description 
GIBCO, cat # 11875-093 0.1 micron filtered RPMI w/  L-glutamine 
Vector, cat # SA-5004, Horse Radish Peroxidase Streptavidin, 1 mg/mL 
1.75 µL 2-merecaptethanol, 50 mL FCS, 5mL L-
glutamine (lab aliquoted) 
Reagents added to RPMI 
Fetal Calf Serum (lab aliquoted) Added to several reagents 
Ammonium Chloride (lab aliquoted) For red blood cell lycing 
Polyomavirus stock (lab aliquoted) Used in several experiments 
GFP-VP1 lab stock  Provided by Dr. Donald Tipper, at UMMS 
Table 2. General Lab Reagents 
 
FACS, Cell Sort and ELISPOT Reagents 
Source / Catalog Id (if applicable) Description 
FACS Buffer FACS Buffer (1x PBS, 2mL 0.5 mM EDTA, 5mL FCS) 
BD Pharmigen, cat # 553142, lot 41921 Fc Block:, Purified anti-mouse CD15/CD132, 0.5 mg/mL 
BD Pharmigen, cat #553092, lot 41617 B220-APC: APC anti-mouse CD45R/B220 (RA 3-6B2), 0.1 mg/mL 
BD Pharmigen, cat # 5527655, lot # 45976 CD19-APC: APC-Cy7 labeled anti-mouse CD19 (1D3), 0.1 mg/mL 
UNLB, cat#  1010-01, lot F5004-T435 Anti-Ig: Goat-anti mouse Ig (H+L), Human, Absorbing, 1 mg/mL 
Zymed, cat # 61-0140, lot 404874312 Biotin-Rabit-Anti-Mouse IgG1, 1 mg/mL (detecting antibody) 
Vector, cat # BA-2020, lot Q0810. Biotin-Anti-Mouse-IgM, mµ chain specific, affinity purified, made in 
goat, 1 mg/mL (detecting antibody) 
Sigma, cat # N2876-100 UN, lot# 
083K8630 
Neuraminidase – from clostridium perfringes, (lyophilized powder, 
resuspened at 50 U/mL in PBS for stock solution) 
Sigma, cat # D158550-1L, lot # 09708PC N,N-Dimethylformamide 99% 
Sigma, cat # A-6926, lot # 123K8204 3-Amino-9-Ethylcarbazole 20mg 
Table 3. FACS, Cell Sort and ELISPOT Reagents 
 
ELISA Specific Lab Reagents 
Source / Catalog Id (if applicable) Description 
VP1 (lab aliquoted) Used for coating (1mg /mL) 
Irrelevant Rat B-cell Hybridoma M5/114.152 (IgG2b) hybridoma 
VP1 specific Rat B-cell Hybridoma (IgG2b) provided by Aaron Lukacher's lab at Emory University 
Whey Dilution Buffer (lab aliquoted) For dilution of antibodies/samples 
Jackson Immuno Research Laboratories Inch, code 112-
095-068, Lot # 55638. 
1.5 mg/mL, of FITC-conjugated, Affinipure, Goat, anti-
rat IgG + IgM (H+L) 
BD Pharmigen, cat # 553653, lot # 0000080777. PE anti-mouse CD4 (L3T4) (H129.19) 0.2 mg/mL 
Zymed, lot # 10602944. Biotin-Mouse-Anti-Rat kappa It chain, 1 mg/mL 
Vector, cat # BA-4000, lot # E0727 Biotinylated, Anti-Rat (H+L) Affinity purified, Made in 
Rabbit, 1.5 mg/mL 
Table 4. ELISA Specific Lab Reagents 
 
 
General Lab ELISA Assay 
 ELISAs were performed to quantitate the levels of VP1-specific antibodies (VP1 
coating), or to determine general serum levels of IgG2a, IgG2b, and IgM .  VP1 coating of a 96-
 18 
well microtiter dish was performed by adding 3.5 µl of a 1 mg/ml stock of VP1 protein in 20 
mM Tris pH 7.2, 1 mM EDTA, 5% glycerol, 1.0 M NaCl (provided by Bob Garcea) to 10 ml of 
Carbonate Buffer.  100 µl was added per well, except for control wells, then the plate was 
incubated in a humid box (Tupperware box lined with a wet paper towel) overnight, or at room 
temperate for 2 hrs minimum.  The blocking solution was discarded, and replaced with 150 µl 
per well of Blocking Buffer (5% non-fat dry milk dissolved in Whey Dilution Buffer: 4% Whey, 
0.5% Tween-20, 1x-PBS).  The incubation was continued for at least 2 hrs. The blocking buffer 
was discarded, and the wells were washed once for 1 min with 150 µl per well with 2x Wash 
Buffer (0.2% Triton X-100 in 1x PBS).  The wash was removed and immediately replaced (so 
the well does not go dry) with 100 µl of sample diluted in Whey Dilution Buffer, usually using a 
1:500 sample dilution.  Controls included no serum, no HRP, and non-viral serum.  Plates were 
incubated at room temperature for at least 2.5 hrs.  The sample serum was discarded, and the 
plate was washed twice 1 min each with 2x Wash Buffer, never allowing the well to dry. 
 When detecting IgG and IgM, 100 µl per well of isotype-specific biotin-labeled antibody 
(1:1000 dilution, 10 µL/10 mL Whey Dilution Buffer) was added, and incubated for 1 hour.  The 
wells were washed twice in 2x Wash Buffer, then 100 µL/well streptavidin-HRP (1:500 dilution,  
20 µL/ 10 mL Whey Dilution Buffer) was added, and the plate left at room temperature for at 
least 1 hour.  When detecting IgA, IgG1, IgG2a, IgG2b, and IgG3, 100 µL/well of isotype- 
specific-HRP (Southern Biotech) (1:1000 dilution) was added (except to the HRP control), then 
the plates left at room temperature for at least 1 hour.   The HRP soultion was discarded, and the 
wells were washed 2-3 times with 2x Wash Buffer. 
 The color forming reaction required the preparation of fresh TMB (Tetramethyl 
benzidine, Sigma) by dissolving 1 mg TMB tablet in 5 ml of 0.1 M phosphate/citrate buffer and 
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5 mL of water.  2 µL of  30% H2O2 was added just prior to use, and mixed thoroughly.  100 µL 
of this TMB substrate was added per well, and the plate was incubated at room temperature for 
2-5 minutes.  The positive wells were blue.  The reaction was stopped by adding 25 µL/well of 
2N H2SO4, then the OD was measured at 450 nm. 
 
ELISA – General Antibody 
The general lab ELISA protocol (above) was modified to determine the total Ab titer in 
hybridoma supernatant. A coating of Anti-rat IgG + IgM (Jackson Immuno Research 
Laboratories, cat# 112-095-068) was made by adding 3.5 µL per 10 µL Whey Dilution Buffer. 
All steps were performed as described earlier. Samples used were, supernatant from irrelevant 
and VP1-specific hybridoma. As standard practice, a positive control (day 14 polyomavirus 
infected mouse sera) and negative control (uninfected mouse sera) samples were also plated out. 
Each was compared at an initial dilution of 1:500 (diluted in Whey Dilution Buffer), and a 1/3 
dilution series performed on the ELISA plate. A stock antibody was also used to calculate 
hybridoma antibody concentrations. The stock antibody used was PE anti-mouse CD4 (BD 
Pharmigen, cat # 553653) diluted identically to the samples.  All subsequent steps were 
performed normally as described above. A Zymed, Biotin-Mouse-Anti-Rat kappa light chain (1 
mg/mL) antibody was applied as the capture antibody. Every other step was done as in the 
general protocol. 
 
ELISA – Hybridoma VP1 - Specific 
 A two plate ELISA was also performed to quantitate the amount of VP1 specific Abs in 
VP1 Specific and Irrelevant hybridoma supernatants. A standard VP1 coat was applied to two 
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plates. In exception to coat, plate 1 was carried out identically to the general antibody ELISA. 
Plate 2 differed in the use of a separate capture antibody. The capture antibody used was an Anti-
Rat (H+L) (Vector, cat# BA-4000) antibody. 
 
VP1-FITC labeling 
 For the initial VP1 staining, a labeling of FITC was done with a Pierce, EZ-label FITC 
Protein labeling kit. The VP1 sample labeled was at a concentration of 1 mg /mL. The labs stock 
was not in the correct buffer. BupH ™ Borate Buffer (pH 8.5) buffer was required for use in 
labeling. Thus, dialysis was performed using 50 µL of VP1 to get VP1 into the BupH buffer. The 
complete protocol for the dialysis is found on Page 3 of the labeling kit’s instructions for 
“Removal of Excess Fluorescent Dye – For sample volumes of 100 µL or less.  100 uL of VP1 
was dialyzed and split into two tubes (stained, unstained).  To accomplish the labeling, FITC dye 
prepared by mixing 100 µL Dimethylformaide (DMF) to a pre-weighed FITC tube (both 
included in kit).  It was determined that 1.1 uL of prepared FITC was needed to label 50 µL of 
VP1.  1.1 µL of FITC was added to stained tube, and allowed to incubate at room temperature 
for 1 hour.  PBS was then mixed up (also included in kit), by adding a PBS packet to 500 mL of 
water.  PBS is needed for second dialysis to remove excess dye.  Another dialysis reaction was 
performed (1 hour), but instead used PBS in place of the BupH buffer. The VP1-FITC was then 
ready, and stored in a light block tube @ 4°C until future immuno-staining.   
 
General FACS Protocol  
The lab’s basic FACS protocol was modified.  Spleens were isolated from mice. Then, 
each spleen was ground in FACS Buffer using microscope slides (frosted ends). The cell 
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suspension was filtered through an RBC filter (neoprene mesh).  The cell suspension was spun 
down (1330 rpm @ 4°C for 5 min), and the supernatant was discarded.  The cells were 
resuspended in 5 mL (per spleen) of 155 mM NH4Cl (kept on ice) and incubated for 5 minutes at 
room temperature to lyse red blood cells. Then the cells were washed twice with PBS and  
resuspended in PBS (1x) at 10
7
 cell/ml cell density. 
Generally, 200 µL or 250 µL of cell suspension was added per well (depending on the 
experiment): a control well for each fluorescent antibody used, and unstained control well, and 
any sample wells (infected, uninfected, enzyme treated, negative controls, etc.) 
The plate was spun down, then Fc Block was added to each well, 100 µL / well (1:100 dilution,  
20 µL Fc block / 2 mL FACS). Cells were then incubated in the dark (wrapped in tinfoil) for 30 
minutes at 4°C.  The plate was spun down, and the cells were washed by adding 200 µL/ well of 
FACS buffer, then they were spun down again. The washing process was repeated 2 times. 
Staining then proceeded by adding 100 µL/well staining antibody cocktail at 1:100 dilution 
(diluted in FACS buffer) to sample wells (I always made a little extra cocktail). A typical 
cocktail example for 7 Samples: added 8 µL of each antibody to 800 µL of FACS buffer, then 
added 100 µL / well.  For control wells, 100 µL FACS buffer and 1 µL staining antibody was 
added, for unstained control no antibody was added. The plate was incubated in the dark 
(wrapped in tinfoil) for 30 minutes @ 4°C.  After incubation the plate was spun down and 
washed 2 additional times (w/FACS buffer). Finally, the cells were fixed by adding 100 µL / 
well Cytofix
TM
 (paraformaldehyde) and incubated at room temperature for 2 minutes. 100 µL per 
well FACS buffer was then added, samples were usually run the next day on LSR II.   
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FACS Protocol w/ Neuraminidase Treatment and GFP Stain 
When performing a plate with neuraminidase treatment, the cells had to resuspended 
between 1-3 million cells/ mL or the treatment would not work. The protocol was the same as the 
general one, but the treatment step was placed prior to the Fc Block step.  Neuraminidase 
(Sigma, type V, from clostridium perfringes) was used at a concentration of 1 unit /mL 
(dissolved in TC-PBS 1X).  Diluted neuraminidase was then added 200 µL/ well and the plate 
was allowed to incubate at 37°C for 1 hr.  The plate was washed 2-3 times (spun down, washed) 
with 200 µL/well with FACS Buffer. Then the plate enters the normal Fc block stage. 
For a GFP-VP1 stain, only 0.1 µL GFP-VP1 for 100 µL well was needed (0.1 µL/ 100 
µL PBS).  This step was done after the Fc Block step.  A GFP-VP1 stain was optimally done to 
separate this reagent from any other staining antibodies, and it was diluted in PBS instead of 
FACS buffer. After incubating for 30 minutes at 4°C, the plate was spun down (1330 rpm @ 4°C 
for 5 min).  The plate was flicked, and its wells were washed by adding 200 µL/ well of FACS 
buffer.  Generally 2-3 washes were done after the GFP stain. Any additional staining then 
proceeded after the GFP stain. 
 
FACS Protocol/ Cell Sort 
Five spleens from C57BL/6J spleens at day 7 of infection with 2 x 10
6
 pfu of 
polyomavirus were isolated for staining.  The cells were prepared as described in the FACS 
protocol section. The staining itself was then done using 500 million cells at 10 million cells/mL 
(50 mL total volume). A plate was prepared concurrently with control wells. 200 µL of 
suspension was added per well, and spun down. A control well for each fluorescent antibody 
used (APC-B220 and GFP-VP1) was done. Both the 50 mL conical and plate were spun down 
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(1330 rpm @ 4°C for 5 min) and the supernatant was discarded.  The Fc block was then added to 
each well, 100 µL / well (1:100 dilution,  i.e. 20 µL Fc block / 2mL FACS).  The Fc Block was 
also added to a 50mL conical tube (500 µL Fc block / 50 mL FACS). The plate and 50 mL 
conical were incubated in dark (wrapped in tinfoil) for 15 minutes @ 4°C. 
 Both samples were then spun down, and washed once (100 µL/well of FACS buffer, and 
50 mL of FACS buffer in tube).  Staining antibodies were added (100 µL/well) to control wells: 
1 µL APC-B220 / 100 µL FACS Buffer , and 0.4 µL GFP / 100 µL FACS Buffer. For the 50 mL 
conical tube (main stain), 90 µL of APC-B220 was added, and 50 µL of GFP-VP1 was added in 
50 mL of FACS buffer (90 µL APC-B220 + 50 µL GFP-VP1/50 mL FACS buffer). Stains were 
incubated in the dark (wrapped in tinfoil) for 30 minutes @ 4°C. 
The conical tube was resupended at 30 million cells /mL (~13 mL).  The sample at 30 
million cells/mL was placed into snap cap tubes. Control wells were pipetted from the plate to 
bullet tubes.  Collection media was made (50% FCS – 20 mL, 50% RPMI -20 mL) for the 
collection of cells after sorting. Cells were sorted in the UMMS sort facility (~4 hours) into two 
populations. One population sorted out was APC-B220+ lymphocytes, and the other were APC+ 
/ GFP-VP1+.  During the time the cells were being sorted an ELISPOT plate was coated with 
VP1 (1 mg/mL), anti-Ig (1mg/mL) or no coat control.  The coat was made by adding 3.5 µL of 
VP1 or anti-Ig to 10 mL carbonate buffer. VP1/Anti-Ig/No Coat were used to coat 2 columns 
each.  The ELISPOT plate was allowed to incubate for 4 hours at 37°C. After coating, the plate 
was blocked by adding RPMI + 10% FCS and incubated for 30 minutes at 37°C.  After cell sort 
was finished cells were given 30 minutes to discharge (they are fragile). 
The APC+ and APC/VP1 double-positive (+/+) sorted samples were spun down and 
resupended at maximal cell density to be still be able to coat 6 wells (266 µL each, i.e at least 
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1600 µL of  each suspension was needed).  APC positive cells were resuspended at 5 million 
cells/mL, and double positive cells were resuspended at 500,000 cells /mL (suspension media 
used was 10% FCS and RPMI).  Media + 10% FCS was added (200 µL/well) to all wells except 
the top row.  In the top row, 266 µL of either APC + (first 6 wells) or +/+ (last 6 wells) was 
added of the cell suspension. A ¼ dilution was then performed by removing 66 µL of cells from 
the top row and continuing down the plate. The plate was allowed to incubate at 37°C for 4 
hours. During the incubation time, detecting reagent was made. 11 mL ELISPOT wash (1X PBS, 
0.1% Tween 20) was added to 220 µL FCS, 11 µL anti-IgG biotin, and 11 µL anti-IgM – Biotin. 
After incubation, the plate was flicked, and washed 3 times with 150 µL/well ELISPOT 
wash buffer. Detecting reagent was added to all wells (100 µL/well) and the plate was allowed to 
incubate overnight at 4°C in a humid box (to prevent drying out). The plate was washed 3 times 
with 150 µL/well ELISPOT wash buffer. Streptavidin-HRP solution was made by adding 220 µL 
FCS, and 11 µL SA-HRP to 11 mL ELISPOT Wash Buffer. The SA-HRP was added (100 
µL/well, and the plate incubated at room temperature for 45 minutes. The plate was then washed 
3 times with ELISPOT Wash Buffer (150 µL/well). Developing reagent was made by placing a 
20 mg AEC tablet (Sigma) in 2mL of DMF (N,N-Dimethylformamide). The solution was 
vortexed, and 1 mL was added to 30 mL of 0.1 M Sodium Acetate. Developing Solution was 
then filtered through a 0.2 micron (or 0.4 micron) filter. Immediately before developing, 15 µL 
of H2O2 was added to the solution and then pipetted 100 µL/well on plate. After 5 minutes of 
plate developing, brown spots appear.  The plate was then washed vigorously with water and 
given time to dry. 
* Alternative Neuraminidase Method:  before the Fc Block, cells were resuspended at 1 
million cells / mL in PBS, then treated with 40 Units of neuraminidase per 400 million cells for 1 
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hr @ 37°C. Cells were washed 3 times in FACS buffer, and then resuspended at 10 million/cells 
mL for staining. 
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RESULTS 
   
 The original goal of this project was to sort out antigen-specific (VP1) B-cells using 
FACS staining.  Mice were infected i.p. with PyV, then splenocytes were taken during the peak 
of infection (day 7).  B-cells specific to VP1 are very low percentage, thus taking them from a 
pool of infected mice increases the chances of selecting for such cells. A double stain for B220 
(CD45R) (a B-cell-specific marker) and VP1 viral capsid should produce a small percentage of 
double positive cells that are both B-cells (B220+) and antigen specific (VP1). The problem was 
that B-cells (and most other cells) contain sialic acid residues which also bind VP1, producing 
non-antigen specific staining. 
       Why search for such cells in the first place, particularly primary cultures? The 
argument can be made that B-cells in culture are not accurate representations of an intact 
immune system response. Methods similar to this project have been used, but never with primary 
splenocytes. As these double positive cells are such a low percentage of naturally occurring B-
cells, it made the project a bit more challenging. But once enrichment for such B-cells succeeds 
they can be studied on the genomic level. What exactly makes those cells so special during, 
before, and after viral infection can be learned. 
 The first method used to reduce non-specific binding was to use neuraminidase to cleave 
the sialic acid residues present on the surface of the cells prior to staining with VP1.  The 
strategy is shown in figure 8 below.  With non-specific binding of VP1 to sialic acid minimized 
(right panel), more VP1 should be free to engage viral-specific antibody on the B-cell surface. 
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Figure 8. Theoretical Neuraminidase Treatment.  VP1 major capsid protein (that binds cells) is able to bind 
terminal alpha 2,3 sialic acid residues (left panel), thus neuraminidase needs to be used to remove sialic acid (right 
panel), leaving surface IgG as the primary means for binding the VP1 stain.  Modified from Caruso et al., 2003. 
 
VP1-FITC Stain 
 Initially, VP1 was labeled using a FITC labeling kit. Sometimes the staining looked fairly 
good, but this was not reproducible.  One would expect more VP1-specific B-cells in the spleen 
of PyV- infected mice, but the staining with VP1-FITC was inconsistent.  Neuraminidase 
treatment was attempted using the VP1-FITC and B220 stains. Neuraminidase is used by several 
bacteria and viruses to degrade sialic acid residues. Influenza virus uses neuraminidase, as it 
cannot bind effectively with sialic acid present. Without neuraminidase to remove sialic acids, 
influenza is unable to enter host cells and infect them. This is interesting, because polyomavirus 
uses the same sialic residues as a receptor. If sialic acid residues are removed, polyomavirus is 
unable to bind and be endocytosed by the host cell. Thus, neuraminidase is being used to prevent 
viral binding of PyV, rather than allow its entry as in influenza (fighting fire with fire). After 
treatment it was hoped that the sialic acid receptors would be removed and only B-cell receptors 
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would continue to bind fluorescently labeled-VP1, making isolation of such cells easier.  Figure 
9 shows the best VP1-FITC stain achieved without neuraminidase. The top right quadrant (high 
staining for B220 + VP1) contains 0.74% of the cells in the infected sample versus only 0.56% in 
the uninfected (0.014% to 0.036%). B220 staining is also increased in the infected sample, as 
would be expected during the peak of any infection (42.2 % versus 57.4 %). During an 
infection’s peak (day 7-8) viral titer is high and the amount of antigen-specific B-cells fighting it 
increases. Even so, the total percent of these B-cells is very small, much less than one percent of 
all B-cells. Therefore, many events (cells) much be sampled in order to see any difference in 
infected samples, or to get a significant amount of antigen-specific B-cells.  
 
 
 
 
 
 
 
 
 
 
Figure 9.  FACS Analysis of Uninfected and Infected Murine Lymphocyte Samples Stained with VP1-FITC.   
Uninfected splenocytes (left panel) and infected (right panel), both using 1:100 dilution of VP1-FITC. 
 
 
 
 VP1-staining had hints of success, but unfortunately a new batch VP1-FITC frequently 
had to be prepared, with each labeling reaction producing different staining results. It was 
concluded that trying a dilution of VP1-FITC may be more effective at reducing background (see 
figure 10).  
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             One would hope that the B-cell receptors specific for VP1 would have a much higher 
affinity then a common sialic acid residue (present on most cells Therefore dilutions of FITC-
VP1 were first performed to determine a point where most of the double positive cells were those 
desired antigen specific cells. Since, if there was an excess of FITC-VP1 it would bind not only 
to specific B-cell receptors, but then the extra VP1 would bind sialic acid residues. 
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Figure 10. Effect of Diluting the VP1-FITC Lymphocyte Stain.   Data shown in paired panels, uninfected (left) 
and infected (right).  Highest amounts of VP1-FITC stain are shown in the upper left, and the most dilute in the 
lower right. 
 
 
      The background was significantly reduced using 0.1 µL stain instead of 1 µL, but the 
infected samples contained less double positives (upper right quadrant), not consistent with 
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infection. During an infection, one would suspect more of such cells. The VP1-FITC approach 
was tested several more times, with and without neuraminidase, but it was still not reproducible. 
 
VP1-GFP Stain 
 In place of VP1-FITC it was decided to use a genetically engineered VP1-GFP made in 
yeast.  A large amount of this reagent was obtained, alleviating the issue of having to constantly 
make new batches. It was also less likely that it would have any cross-reactive dye since the 
dialysis after the FITC labeling reaction never removed 100% of the un-reacted FITC, which 
may have contributed to irregular staining. Also the neuraminidase used was changed to Sigma 
brand, as the New England Biolabs was ineffective, even at extremely high concentrations. The 
dilution of neuraminidase, temperature of incubation, and what the enzyme was dissolved in 
were changed over many experiments.  Some papers suggested 37˚C, others 4˚C, and no paper 
gave a real definition of how many units of neuraminidase should be used per given amount of 
cells.  Such variables made it difficult to optimize the stain, however using the VP1-GFP did 
produce uniform staining throughout the assay optimization.  
 Several dilutions were tested of the VP1-GFP stain, and it was determined that 0.1 µL per 
100 µL well produced the same results as 1 µL, so this 10-fold dilution was used for the rest of 
the project.  Likely the GFP-VP1 is at higher concentration than FITC-VP1 (confirmed by 
ELISA).  Unlike with VP1-FITC, the GFP-VP1 staining was virtually the same every time 0.1 
µL/ 100 µL well was utilized. Some of the earliest data using this staining dilution is shown in 
Figure 11 below.   In Figure 11, uninfected and infected lymphocytes were stained using VP1-
GFP and CD19-APC (another B-cell marker often used in place of or concurrently with B220).  
Staining with CD19 provided identical data as B220 when both were used. 
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Figure  11. Early GFP Neuraminidase Lymphocytes Stain. Left column contains uninfected samples, and right 
contains infected. The top row is treated with 1 u/mL neuraminidase, middle with 200 mu/mL and the bottom is a 
negative control for treatment.   
 
 
Also in this figure, 200 µL/ well of neuraminidase dissolved in PBS was used to treat 
infected and uninfected lymphocytes.  Concentrations of 1 u/mL and 200 mu/mL and a negative 
(untreated row) were tested.  In the upper left panel of each set (VP1-positive cells that are not 
B-cells) for uninfected samples (left column), 1.73% non-neuraminidase-treated (bottom row) 
was reduced to 0.68% using 1 u/mL neuraminidase (top row), and to 1.15% using 200 mu/mL 
(middle row).   In virally exposed samples (right column), 1.37% was brought down to 0.8% 
using 1 u/mL, and to 1.03% using 200 mu/mL.  These are non-B-cells, thus such dramatic cut 
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downs in VP1-positive cells are indicative of a working neuraminidase treatment. Reduction of 
non-B-cell receptor binding is also seen in the upper right quadrant (B-cells).  The 
subpopulations (circled) in the upper right quadrant that are lower VP1 staining (middle),  show 
a large reduction after neuraminidase treatment. Thus, the other super populations, likely contain 
the true double positives.  Such data suggests that the 1 u/mL concentration was a bit more 
effective.  A few other stains produced similar results. 
 
 Using the GFP-VP1, it became clear that the neuraminidase treatment works best under 
the following conditions:  0.2 units of neuraminidase in 1X PBS (1 Unit/mL per well), at low cell 
densities, and at 37°C.  Even so, we questioned how well GFP-VP1 actually binds sialic acid 
residues and B-cell receptors. ELISA data confirmed GFP-VP1 is more concentrated than 
unlabeled VP1 or FITC-VP1 (each was used as a coat, and infected serum with antibodies was 
used as a sample in ELISAs). Yet, this did not confirm that B-cell receptors where actually 
responsible for the specific binding.                 
 Therefore, two rat isotype-matched (IgG2b) B-cell hybridomas were obtained. One 
hybridoma was specific for VP1 of polyomavirus, and the other was an irrelevant (M5/114.152) 
rat hybridoma.  In theory, the specific hybridoma should stain with a higher affinity for GFP-
VP1 if it truly staining specifically.  This experiment is detailed below in Figure 12. 
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Figure 12. Hybridoma Comparison Stain.  Positive Hybridoma is VP1 specific and Negative Hybridoma in non 
specific. Top row is neuraminidase treated, and bottom is untreated. The last column contains a comparison of the 
fluorescence of the large group (all B220+). The first number is the % of cells and the last number is the main 
fluorescence intensity. Key: 10X; (1:1000 fold dilution), neg Hy =  negative hybridoma, pos Hy = VP1-specific 
hybridoma,. 200 mu Neura. = 200 mu of neuraminidase.  Neg Neura = no neuraminidase. 
 
  The top row of Figure 12 contains the specific (positive) anti-VP1 hybridoma (left panel) 
and negative (non-specific) hybridoma (middle panel). Both hybridomas produce a IgG2b 
antibody, except the positive is specific for VP1 antigen. The large subpopulations represent the 
B220+ cells which are compared in fluorescence intensity in the 3
rd
 column. Within that is a 
smaller group, gated around VP1-specific B-cells. Neuraminidase treated high affinity B-cells 
compose 5.48% (in the positive control) and drop to 3.17% in the negative. This is congruent 
with the fact anti-VP1 antibody producing cells should have a higher affinity than a non-specific 
0 10
2
10
3
10
4
10
5
B220
0
10
2
10
3
10
4
10
5
V
P
1
-G
F
P
9.3
5.48
Ungated
Specimen_001_Tube_004.fcs
Event Count: 50000
10x GFP, pos Hy, 200mu Neura.
0 10
2
10
3
10
4
10
5
B220
0
10
2
10
3
10
4
10
5
V
P
1
-G
F
P
16.4
3.17
Ungated
Specimen_001_Tube_002.fcs
Event Count: 50000
10X GFP, neg Hy, 200mu Neura.
0 10
2
10
3
10
4
10
5
fluorescence
0
20
40
60
80
100
%
 o
f 
c
e
lls
Specimen_001_Tube_002.fcs 16.4 2647
Specimen_001_Tube_004.fcs 9.3 5524
b220 +
0 10
2
10
3
10
4
10
5
B220
0
10
2
10
3
10
4
10
5
V
P
1
-G
F
P
11.1
6.78
0 10
2
10
3
10
4
10
5
B220
0
10
2
10
3
10
4
10
5
V
P
1
-G
F
P
10.8
1.59
0 10
2
10
3
10
4
10
5
fluorescence
0
20
40
60
80
100
%
 o
f 
c
e
lls
Ungated
Specimen_001_Tube_006.fcs
Event Count: 50000
10x GFP, pos Hy, Neg neura.
Ungated
Specimen_001_Tube_003.fcs
Event Count: 50000
10X GFP, neg Hy, neg Neura.
Specimen_001_Tube_003.fcs 10.8 2365
Specimen_001_Tube_006.fcs 11.1 5456
b220 +
 34 
antibody producing cell. Without this information, one might suspect it was just a non-specific 
antibody (any IgG2b type) with the ability to bind VP1.  It is also quite clear that both 
hybridomas were not pure clones, they contain a lot of non-hybridoma cells. Hybridomas 
unfortunately are not very stable, and often get outgrown by other cells. Regardless, this serves 
as a good positive control.  In the non-treated bottom row, the specific hybridoma still has a 
higher fluorescence as expected. While the neuraminidase treatment reduced binding in the 
specific hybridoma, it appeared to increase in it a small amount in the negative. This increase in 
the irrelevant hybridoma might be due to the sialic acids not being completely washed off the 
cell after cleavage. Other stains have produced similar results. Either way, there is a clear 
increase in the fluorescence intensity for the hybridoma making anti-VP1 antibodies. This would 
support the hypothesis that the GFP-VP1 is staining the antigen-specific B-cells. 
 
Test of Hybridoma Specificity 
 An ELISA was done to confirm that the VP-1 hybridoma produced antibodies specific 
for VP1 (Figure 13) (Y-axis).  The question had been raised over whether VP1 was really 
binding sialic acids / B-cell receptors specifically. Thus, a general antibody ELISA was 
performed (X-axis) where the plate was coated with an antibody targeted to all rat/mouse IgM + 
IgG antibodies. Using such a coat should allow any antibody present in the hybridoma 
supernatant to bind and be detected. Supernatant from each hybridoma was collected to have its 
antibody concentration assayed.  It was compared to a stock CD4 antibody of known 
concentration. 
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Figure 13. Hybridoma Comparison Using VP1-Specific ELISA.  The y-axis denotes the absorbance values for 
hybridoma supernatant in a VP1-specific ELISA. A quantitative general antibody ELISA was also performed on 
both hybridoma supernatants and displayed on the x-axis. 
 
  Infected and uninfected mouse sera were also tested, and positive and negative controls. 
A dilution series was performed for each antibody-containing sample. As can be seen on the X-
axis, both hybridoma supernatants did contain approximately equal antibody titer. As the 
isotypes are matched, each produces about the same antibody level, the only difference between 
the hybridomas was VP1 specificity. 
 To test the VP1-binding ability of the antibody in the hybridoma supernatants, another 
ELISA was completed using VP1 as a coat to only bind VP1-specific antibodies instead of all of 
them. Two contrasting plates were done using different capture antibodies. One plate used the 
mouse-anti-rat kappa light chain capture antibody, and another with rabbit anti-rat IgG antibody. 
The rabbit anti-rat appeared to produce a more consistent dilution curve, possibly as the reagent 
was much fresher. Even so, both yielded data that confirmed much higher absorbance levels for 
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VP1-specific hybridoma (Y-axis in figure 13). At higher antibody concentrations it is clear that 
the VP1-specific hybridoma reacts much brighter than the irrelevant hybridoma. As antibody 
concentrations decrease, so does the VP1-specific absorbance in the specific hybridoma. 
Conversely, the irrelevant hybridomas VP1-specific absorbance says at background levels 
regardless of concentration. Such data was completely congruent with the fact the specific 
hybridoma does indeed produce antibodies specific for VP1. It also confirmed that the GFP-VP1 
truly binds specific antibodies for VP1, and it’s not caused by GFP or any other cross-reactive 
cell property. 
 
Cell Sorting 
 With all the data supporting the dual GFP-VP1 and B220 stain as valid, an attempt was 
made to select for the double positives in hope of seeing enrichment for primary VP1-specific B-
cells isolated from mice spleens. To accomplish this, a pool was done of 5 infected mice, an 
optimized stain performed, and the double positive B-cells sorted. The cells were then tested in 
an ELISPOT assay (see Materials and Methods). Unlike an ELISA, an ELISPOT assay yields 
information about living cells (and their ability to secrete hormones) rather than a static dead cell 
component without an intact membrane. This sorting experiment is the climax of the entire 
project. The purpose was to isolate VP1-specific living primary B-cells for analysis. If the cell 
sort selecting for double positives was performed, and the ELISPOT confirmed an enrichment of 
VP1-specific B-cells, gene expression studies could be performed in the future. See figure 14 for 
a graphical representation of the process. 
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Figure 14. Process for Selecting Antigen (VP1)-Specific B-Cells.  Cells are first stained with fluorescently labeled 
VP1 followed by B220 (b-cell marker). Double positives and B220 positives were sorted out and compared via 
ELISPOT. The goal is to use this method to compare the enriched population for differences on the genomic level. 
 
 
 A double stain was performed, and two populations were isolated by a FACS cell sort. 
No neuraminidase treatment was used since neuraminidase treatment often adversely affects cell 
viability (notable in some earlier staining). It was hoped the amount of GFP-VP1 staining would 
be high enough so that a majority of specific B-cell receptors would stain preferentially over 
lower affinity sialic acid residues. Two populations of B220-APC + (B-cells) and double-
positive cells (B220-APC/VP1-GFP) were isolated.  In theory the double positives should show a 
large enrichment for antigen specific cells. A VP1-specific ELISPOT was performed using both 
populations (Figure 15).    
 
VP1-GFP/B220-APC +/+  (500,000 /mL) B220-APC + Only (5 Million /mL)  
  Ig   Ig VP1 VP1 NC NS  Ig  Ig VP1 VP1  NC  NC 
1:1   x    x   x   x  x   -   x   x  10   8   6   7 
1:4   x    x  25  27 12   -   x   x     
1:16   x    x       x   x     
1:64  37   71       x   x     
1:256        32   8     
1:1024             
Figure 15. ELISPOT Data for APC-Positive B-Cells and Double-Positive VP1 B-cell Populations. Left column 
is the dilution of sample. Key: Ig = Ig coat on plate, VP1 = VP1 coat on plate, NC = no coat, NS = no sample, x = 
too many spots to count, - = no spots. 
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Approximately 10.33 ·10
6
 APC-positive cells and 6.574 ·10
5
 double-positive cells were isolated 
from approximately 400 million splenocytes via a FACS cell sort. APC-positive cells were 
resuspended at 5 million cells/mL, and double positives resuspended at 500,000 cells /mL, these 
cells were then tested in an ELISPOT for specific VP1 and general antibodies (Ig) (see Figure 
15).  It is evident that not only are the double-positives enriched for VP1-specific B220+ cells, 
but also for antibody secreting cells. Even with the +/+ cells at lower dilution (500,000/mL 
versus 5 million/mL), the plate had a tremendously increased amount of colonies (spots) for both 
VP1 and Ig.  Additionally, the +/+ took a higher dilution just to be able to count the amount of 
VP1-specific colonies.  Uncoated lanes were done as negative control, so that the actual amount 
of VP1-specific colonies could be determined.  Double positives only had one such lane as there 
was only a limited amount available (even with a cells sort, only a limited amount can be 
obtained). With such data the percent of VP1 specific cells can be elucidated, along with the 
increase enrichment, as shown in Figure 16. 
 
 VP1-GFP/B220-APC +/+  B220-APC + Only  
Countable  
Concentration 
125,000 cells /mL 5 Million /mL 
µL / well 200 200 
Initial # cells / well 25,000 cells/ well 1 million cells / well 
Average # VP1 colonies 26 9 
Background (No coat) colonies 12 6.5 
Actual Vp1 colonies (ave. – NC) 14 2.5 
Concentration of specific VP1 
colonies 
14 colonies /25,000 cells 
= 5.6 x ·10-4 colonies / mL 
2.5 colonies/1 million cells 
= 2.5 x ·10-6  colonies /mL 
Percentage of cells (14/25,000)(100) = 0.56 % (2.5/1,000,000)(100) = 
.00025% 
% Enrichment (0.56)/(0.00025) = 224 times more or 22400% 
Figure 16. Enrichment Calculations for the ELISPOT Data. 
 
      Calculations (see figure 16) show that there were 224 times greater (22400%) enrichment for 
VP1-specific cells in the double positive population compared to the starting population.  This 
augmentation should be more than enough to see changes on the genomic level. The double 
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positives contained 0.56% VP1-specific B-cells, and only 0.00025% in the B220+ samples. 
Neither number is incredibly high, as such cells are quite rare in vivo. Despite this, the 
enrichment did work! The projects main aim was achieved. The only way to improve the purity 
even more would be to use neuraminidase. 
 Neuraminidase treatment optimization was tested (temperature, dilution, buffer, 
incubation time), using an increasing dilution of cells (10 million, 3 million, and 1 million cells 
/mL (see Figure 17). 
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Figure 17.  Neuraminidase Cell Dilution Stain.  Only uninfected splenocytes were tested.  A 1:1000 (10 fold 
dilution of normal) GFP stain was performed on different cell dilutions. The top row contains cell dilutions of 10 
million/mL, middle 3 million/mL, and bottom 1 million/mL. Left columns are 1U/mL neuraminidase treated 
samples. While the right column contains untreated samples.  Note the reduction in VP1 binding in the upper 
quadrants. 
 
 The percent of VP1-positive cells decreased dramatically in both B220 + and B220 
negative upper quadrants in the lower cell dilutions. The upper left quadrant (non-B-cells 
staining for VP1) showed a large decrease in both the 1 and 3 /million cell dilutions. Most of the 
staining during the project was done at 10 million cells /mL to facilitate the FACS analysis. But 
the neuraminidase enzyme is fairly inefficient; therefore the lower cell dilutions work 
significantly better. Such dilutions produce more reduction of non-specific binding to sialic acid 
residues. Moreover, the ratio of enzyme to cell numbers would increase (which would settle less 
as well).  Neuraminidase was probably overwhelmed with the amount of substrate (sialic acids) 
at higher dilutions. It’s also possible, cell density was so high that cells clumped and just did not 
allow neuraminidase to even access the sialic acids. 
 When expanding this approach to infected and uninfected splenocytes (see Figure 18), 
the infected sample did contain more VP1/B220 double positives as expected. Additionally, the 
infected samples had a lot more B220+ B-cells in general (bottom left quadrant) in the infected 
samples. Neuraminidase treatment decreased the amount of B-cells in the infected samples, from 
73.6% to 59.8%.  Both upper right quadrants in infected and uninfected samples showed 
decreased VP1 binding.  The difference is more drastic in the infected samples (0.86% to 
0.67%).   
 Using this neuraminidase treatment, another FACS stain (Figure 18), cell sort, and 
ELISPOT (Figures 19 and 20) were performed. The experiment was a repeat of the previous 
experiment (pool of 5 infected mice), only the neuraminidase treatment was done. 
 41 
 
Figure 18.  FACS Analysis of Infected and Uninfected Cells Using Neuraminidase at a Low Cell Density. 
Uninfected (top row) and infected (bottom row) splenocytes were used.  A 1:1000 (10 fold dilution of normal) GFP 
stain was performed on different cell dilutions.  All cells were stained at a concentration of 1 million cells/mL. Left 
column are 1U/mL neuraminidase treated samples. While the right column contains untreated samples, note the 
reduction in VP1 binding in the upper quadrants, especially in the infected samples. 
 
      For this neuraminidase treatment, the cells were resuspended at 1 million cells / mL, and 400 
million cells were treated with 40 Units of neuraminidase for 1 hr @ 37°C.  Unfortunately, this 
treatment appeared to be too harsh to the cells. Of 400 million cells, only about 40 million 
survived. Another plate was also done with unsorted infected and uninfected cells. This plate 
served as a control to make sure infected mice do have a larger amount of VP1–specific cells. 
The data for both plates are present in figures 19 and 20. 
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VP1-GFP/B220-APC +/+  (43,000 /mL) B220-APC + Only (1.875 Million /mL)  
  Ig   Ig VP1 VP1 NC NC  Ig  Ig VP1 VP1  NC  NC 
1:1   x   x    -          -    -    -   x   x    x         X    -    - 
1:4   x   x    -    -   -    -   x   x    X    X   -    - 
1:16   10   9    -          -   -     -   x   x    5         9   20    22 
1:64             x   x    -    -   
1:256            7   9    -     -    3    4 
Figure 19. ELISPOT Data for APC + and Double-Positive Populations with Neuraminidase Treatment. Left 
column is the dilution of sample. Key: Ig = Ig coat on plate, VP1 = VP1 coat on plate, NC = no coat, x = too many 
spots to count, - = no spots. 
 
 
Uninfected Unsorted (20 million / mL)  Infected Unsorted (20 million /mL)  
  Ig   Ig VP1 VP1 NC NC  Ig  Ig VP1 VP1  NC  NC 
1:1   x    x   x   x   x   -   x   x    X    x   x     x   
1:4   x    x   x   x   x   -   x   x    X    x   x   x 
1:16   x    x   x   x   x   -   x   x   23   18   11    8 
1:64   x    x   8  12   2   6   x   x     
1:256   5   10   1   2   1   1   x   x     
1:1024         x   x     
1:4096        14  20   -    -   -   - 
Figure 20. ELISPOT Data for Unsorted Infected and Uninfected Splenocytes. Left column is the dilution of 
sample. Key: Ig = Ig coat on plate, VP1 = VP1 coat on plate, NC = no coat, x = too many spots to count, - = no 
spots. 
 
      This ELISPOT confirmed the presence of more antibody producing VP1-specific cells in the 
infected samples versus the uninfected. Unfortunately the neuraminidase treated cells barely 
showed any spots/colonies positive for Ig or VP1. The plate did have some spots but they were 
infinitesimally small. Perhaps neuraminidase treatment may only be useful from an analytical 
perspective, not for sorting.  Since the entire process works without the neuraminidase by 
limiting the amount of GFP-VP1, such treatment may be unnecessary (and also too expensive). 
As the enrichment (2240%) without treatment was quite good, it will be able to be useful in 
studying the antigen-specific B-cells. 
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DISCUSSION 
 
 
 The purpose of this project was to develop a FACS sorting protocol for isolating PyV 
major capsid protein VP1-specific B-cells from spleens of PyV- infected mice. These cells will 
be studied further for uncovering pathways of B cell responses to virus infection. To achieve this 
unusual enrichment, a double stain for VP1 (antigen specific) and B220+ (B-cell specific) 
proteins was developed. The only problem was that in addition to binding cell surface antibody, 
VP1 also binds cell surface sialic acids causing non-specific binding.  Two methods were 
utilized to get around this. A dilution of VP1-fluorescently tagged stain, and neuraminidase 
treatment of the cells.  A stain dilution should reduce staining to only higher affinity B-cells. 
Conversely, neuraminidase would digest any surface sialic acids that would act as non-specific 
receptors. 
 The research literature was not much help on this project. Other papers using 
neuraminidase poorly specified exactly how treatment was to done. Additionally, no studies were 
published on  treatment of primary B-cells with neuraminidase. Primary cells are a lot more 
fragile than cell lines, thus numerous optimization experiments had to be done before optimizing 
a working stain and neuraminidase treatment. Factors such as temperature, cell density, time, 
incubation reagent were proven to be crucially important. The key was to achieve reproducible 
staining, and acceptable cell viability.  Also, ELISAs and hybridoma stains were performed to 
confirm that the GFP-VP1 molecules were actually binding via VP1 to B-cell receptors (surface 
bound antibodies). Only a VP1-specific hybridoma antibody (at same concentration as an isotype 
matched hybridoma) was able to successfully bind the GFP-VP1 reagent at a limiting dilution.  
 During the course of the experiment both a VP1-FITC and VP1-GFP stain were utilized. 
As time progressed it became clear the VP1-FITC stain did not produce reliable data. Several 
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batches had to be labeled, and each was somewhat different in staining efficacy. Thus, yeast 
produced VP1-GFP was used an alternative. VP1-GFP had the benefit of being highly 
concentrated, allowing all the experiments to be done with the identical reagent. Data from the 
VP1-GFP stains also proved to be much more consistent. Neuraminidase was also used as a way 
to remove background sialic acid staining by removing them. Unfortunately, an effective 
treatment decreased cell viability and proliferation greatly.  Treatment with neuraminidase 
removes sialic acid residues, which are present in high numbers on most cells. With these 
stripped, the cell has a hard time proliferating. The goal of the project was to select for viable 
antigen specific B-cells, which neuraminidase treatment did not prove effective. 
       In the end, a cell sort without neuraminidase yielded the best results, producing 224 times 
more VP1/B220 antigen-specific enrichment, versus a B220-positive B-cell population. When 
the same procedure was done with a neuraminidase treatment known to work at the small scale, 
results were poor, the ELISPOT plate showed only very small spots due to the harshness of the 
neuraminidase treatment on cell viability. Thus, the neuraminidase treatment might be too 
caustic to cells when used in conditions that effectively remove sialic acid.  It is possible that one 
might be able to further improve the conditions, so that cells survive better and that treatment 
still removes background.  
      An alternative method would be to block the sialic acid residues instead of removing them. 
Instead of chewing up the cell surface to remove sialic acids, a sialic acid-binding protein could 
be used.  Possibly the cells would be better of this way. If all the sialic acids could be blocked, 
then only specific-B-cell receptor binding to VP1 should remain. Another advantage would be 
that washing after treatment would not have to be so vigorous. With neuraminidase treatment, 
sialic acid residues might be cleaved, but they could still stick to the cell. Caruso et al (2003) 
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hypothesize that VP1 is only required for the initial cell-virus interaction. That if cleaved sialic 
acid is not completely washed off, they could bind VP1 and allow secondary attachment to the 
cell.  α4ß1 Integrin was shown to be a likely secondary receptor once VP1 is bound to an alpha 
2,3 sialic acid (Caruso et al., 2003). 
     One such possible blocking agent may be Myelin-Associated Glycoprotein (MAG).  MAG 
has a site in its N-terminus that is able to bind certain “sialyated glycans and gangliosides” 
(Vinson et. al, 2001). Vinson and colleagues were able to show that treatment with 
neuraminidase on neuron cells which bind GT1b and GD1a prevented their attachment. Such 
GTlb and GDla receptors, which contain alpha 2,3 sialic acids, stimulate growth which is 
blocked by stripping sialic acid residues.  In another paper (Tsai et al., 2003) show the same 
GT1b and GD1a gangliosides serve as effective polyomavirus receptors. They prepare some 
yeast cell membrane extracts which contain various gangliosides (GT1b and GD1a), treat some 
of the extract with virus, and some with virus and neuraminidase. “Treatment of the ER 
proteoliposomes with α2,3-neuraminidase abolished binding activity” (Tsai et al., 2003). Those 
neuraminidase treated and containing virus showed no virus fractions bound to the yeast extract. 
Whereas virus had bound especially to GT1b and GD1a. They postulate that such gangliosides 
are likely viral receptors.  Moreover, it was shown in the previously mentioned paper that MAG 
binds to both these gangliosides. Such treatment may be very useful in removing background in 
the future. Commercially prepared MAG is often linked to a human Ig domain that can be 
fluorescently tagged.  This could be useful for staining active B-cell sialic acids that could act as 
potential viral receptors. Such data would be quite interesting for receptor and non-specific 
binding studies. 
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      In another paper (Weitkamp et al., 2003), they attempt a similar method to select for B-cells 
that are specific for rotavirus.  They use a double stain for CD19-PE and VLP-GFP (virus like 
particle linked to GFP).  They sort out the double positives, culture them in vitro, put them into 
an ELISA to quantitate antigen-specific cells, and then use them for RT-PCR. From then on 
genes of interest can be cloned into a vector an analyzed. This is similar to the goal of this 
project, except that primary B-cells would be used, instead of cultured. Cultured B-cells are often 
not-representative of a truly viral activated B-cell. The double-positive population would then be 
compared to a B220-positive B-cell population.  Since this project’s enrichment was successful, 
one would hopefully be able to observe an increased amount of certain signals in the double 
positives. These could then be studied even further!  Whether it is by neuraminidase, GFP-
dilution, or MAG blocking methods, there is a bright green future for research of polyoma VP1-
specific B-cells. 
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